Maxim downgraded Citius Pharmaceuticals (CTXR) to Hold from Buy.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTXR:
- Citius Pharmaceuticals Reports Q1 2025 Earnings and Strategic Developments
- Citius Pharmaceuticals reports Q2 EPS (11c) vs. (7c) last year
- Citius Pharmaceuticals Poised for Growth with Key Milestones and Promising Product Pipeline
- Citius Pharmaceuticals target adjusted to $4 for split at H.C. Wainwright
- Biotech Alert: Searches spiking for these stocks today
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue